Nasal drug delivery platform MetP
- fully developed and proven effective and safe
- providing partners with new possibilities for product development
- created by enthusiasts
Nasal drug delivery provides more than therapy of colds or allergies: It enables the administration of systemic-acting drugs with low oral bioavailability and of drugs that are difficult to deliver via routes other than injection.
Furthermore, nasal drug delivery is an excellent – and often ideal – option in the treatment of neurological diseases, including the delivery of biologics with restricted access to the Central Nervous System.
May 8, 2024 — Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells
August 24, 2020 — New nasal gel evaluated for its protective action against human rhinovirus 16 (HRV-A16) infection in nasal epithelial cells
December 9, 2019 — MetP Pharma receives US patent for drug therapy of demyelinating and neuroinflammatory diseases such as multiple sclerosis
October 4, 2018 — MetP Pharma introduces Nascum-Plus against the onset of air pollution-induced inflammation
At MetP, we use our unique nasal drug delivery platform for inhouse product development, and we have already succesfully introduced products into the market.
Claudia Mattern, CSO
Udo Mattern, CEO
Phone +41-41-618 30 30
Email
Nasal applications are possible for a wide range of substances, providing overwhelming benefits. Our proven and patented single-dose nasal applicator Lecticula delivers drugs easily and safely to the systemic circulation and the brain respectively, 100 percent sterile, dosage fully accurate. Our semi-solid formulation Silcum is easily adaptable to a wide range of drugs. Our filling technology Maxima allows to produce pilot samples and to serve mass market. Our own nasally applied drug and OTC products are perfectly well accepted. MetP Pharma AG is a private company and based near Lucerne, Switzerland, held by us, Claudia Mattern, PhD, CSO, and Udo Mattern, CEO.
«What is your molecule? Have it delivered nasally, using our safe formulation and easy to use mono-dose device.»